Zymeworks AI Stock Analysis
Want to see ZYME full AI Analyst Report?
Zymeworks (ZYME) AI Stock Analysis
Zymeworks
(NASDAQ:ZYME)
Overall score is held back primarily by weak cash flow (negative operating/free cash flow) and the sharp increase in debt, despite improved TTM profitability and revenue. Technicals are soft with the stock below key moving averages, while valuation remains elevated (P/E ~39) without dividend support. Corporate events are a relative positive (raised guidance, major partnership/milestone, and buyback), but they do not fully offset cash burn and leverage risk.
Zymeworks (ZYME) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.80B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.04M
- Price to Earnings (P/E)
- 38.3
- Beta (1Y)
- 0.63
- Revenue Growth
- 97.78%
- EPS Growth
- ―
- Country
- US
- Employees
- 279
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Zymeworks Business Overview & Revenue Model
Company Description
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanid...
How the Company Makes Money
Zymeworks makes money primarily through (1) collaboration and licensing arrangements and (2) income related to its own product candidates, if and when they achieve regulatory approval and commercialization. Under collaboration/licensing deals, Zymewo...
Zymeworks Earnings Call Summary
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.
Q1-2026 Updates
Positive Updates
Negative Updates
Company Guidance
The company reiterated near-term regulatory and operational milestones, including a U.S. PDUFA date of 08/25/2026 and an sBLA filing in China for first-line GEA, with near-term approval-triggered milestone payments of $250.0 million (U.S.) and $15.0 million (China) and management citing $440.0 million of anticipated regulatory milestones (U.S./EU/Japan/China) that, together with $403.8 million of cash, cash equivalents and marketable securities as of 03/31/2026 (up from $270.6 million on 12/31/2025), they expect to fund operations beyond 2028 assuming full execution of the $125.0 million repurchase plan; Q1 2026 revenue was $2.4 million versus $27.1 million a year ago, operating expenses were $49.5 million (Q1 2026) versus $52.7 million, and net loss was $44.2 million versus $22.6 million, while share repurchases have used ~$95.8 million of the $125.0 million program to buy ~3.93 million shares at an average $24.37 (total repurchases since 2024 ~ $155.8M for ~8.3M shares at ~$18.70, >10% of shares), leaving ~73 million common shares outstanding; clinical and R&D guidance included ZW191 dose‑optimization (≈60‑patient cohort fully enrolled) with median follow‑up ~7 months, ovarian ORR 56% (>=30% shrinkage in 68%, any shrinkage in 85%, DCR 94%) and at 6.4–9.6 mg/kg ORR 61% with disease control in all patients, endometrial ORR 40% (>=30% shrinkage in 50%, any shrinkage in 70%, DCR 80%) rising to ORR 57% at 6.4–9.6 mg/kg, responses seen from 3.2 mg/kg, ZW1528 IND now guided to 2027 (vs prior 2026), pan‑RAS ADC preclinical program delivered >117 novel inhibitors, three candidate ADCs (ZW439, ZW427, ZW418) were presented at AACR, DAR‑8 format was used, and the lead RAS ADC showed NHP tolerability with no body‑weight, skin or GI toxicity up to 120 mg/kg; additional data cadence was guided toward oncology meetings in 2026 (including ESMO GYN in June).
Zymeworks Financial Statement Overview
Summary
Fundamentals are mixed: TTM revenue and net income improved (positive net income and EBITDA), but balance-sheet risk increased sharply with much higher total debt, and cash generation is weak with negative operating and free cash flow (ongoing cash burn).
Income Statement
56NeutralBalance Sheet
38NegativeCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 265.97M | 105.97M | 76.30M | 76.01M | 412.48M | 26.68M |
| Gross Profit | 261.44M | 105.97M | 76.30M | -66.98M | 412.48M | 26.68M |
| EBITDA | 57.08M | -68.64M | -108.62M | -120.70M | 142.49M | -206.09M |
| Net Income | 43.31M | -81.13M | -122.69M | -118.67M | 124.34M | -211.84M |
Balance Sheet | ||||||
| Total Assets | 1.18B | 346.53M | 463.09M | 580.88M | 648.73M | 389.13M |
| Cash, Cash Equivalents and Short-Term Investments | 100.46M | 228.80M | 225.78M | 374.33M | 492.23M | 252.61M |
| Total Debt | 650.28M | 18.27M | 18.51M | 26.72M | 28.11M | 32.33M |
| Total Liabilities | 918.16M | 78.03M | 124.32M | 116.07M | 155.77M | 140.04M |
| Stockholders Equity | 258.25M | 268.50M | 338.77M | 464.81M | 492.96M | 249.09M |
Cash Flow | ||||||
| Free Cash Flow | -112.33M | -34.53M | -113.11M | -122.38M | 130.98M | -205.74M |
| Operating Cash Flow | -111.69M | -33.01M | -110.04M | -118.30M | 144.11M | -192.45M |
| Investing Cash Flow | -297.64M | 26.66M | 38.76M | -207.25M | -53.85M | 144.60M |
| Financing Cash Flow | 444.83M | -18.56M | -20.45M | 81.85M | 108.58M | 8.01M |
Zymeworks Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZYME, the sentiment is Negative. The current price of 25.84 is below the 20-day moving average (MA) of 28.65, below the 50-day MA of 27.22, and above the 200-day MA of 25.56, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 7.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZYME.
Zymeworks Risk Analysis
Zymeworks disclosed 73 risk factors in its most recent earnings report. Zymeworks reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksZymeworks Peers Comparison
Overall Rating
VIR68Neutral
ANAB61Neutral
XNCR61Neutral
ABCL57Neutral
ZYME48Neutral
GENB41.6Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | $1.58B | -7.40 | -21.38% | ― | 1695.96% | 65.40% | |
| 61Neutral | $1.36B | 7.14 | 906.99% | ― | 13.04% | ― | |
| 61Neutral | $2.59B | -22.05 | -21.29% | ― | 33.55% | 11.51% | |
| 57Neutral | $3.60B | -23.08 | -15.35% | ― | 92.10% | 16.43% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $1.80B | 38.32 | 22.48% | ― | 97.78% | ― | |
| 42Neutral | $1.27B | -4.15 | -146.07% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ZYME | Zymeworks | 25.84 | 3.24 | 14.34% | |
| XNCR | Xencor Inc. | 34.50 | 18.73 | 118.77% | |
| ANAB | AnaptysBio | 45.61 | 20.94 | 84.89% | |
| VIR | Vir Biotechnology, Inc. | 9.25 | 3.81 | 70.04% | |
| ABCL | Abcellera Biologics, Inc. | 11.03 | 7.42 | 205.54% | |
| GENB | Generate Biomedicines, Inc. | 9.84 | -2.81 | -22.21% |
Zymeworks Corporate Events
Zymeworks Authorizes New $200 Million Share Repurchase Program
PositiveZymeworks is a global biotechnology company building a diversified portfolio of healthcare assets while advancing innovative medicines for difficult-to-treat diseases. Its portfolio includes YUPELRI, Ziihera and pasritamig, supported by internal rese...
Zymeworks Reports Quarterly Results, Raises 2026 Guidance
PositiveOn November 9, 2026, Zymeworks reported financial results for the quarter ended September 30, 2026, and raised its 2026 guidance. Total revenue guidance increased to $337 million-$351 million from $278 million-$292 million, while adjusted EBITDA guid...
Zymeworks Announces Global DLL3 T-Cell Engager Partnership
PositiveOn October 22, 2026, Zymeworks entered into an exclusive global collaboration and license agreement with Roche for ZW209, its trispecific T-cell engager targeting DLL3-expressing tumor cells. The deal grants Roche worldwide rights to develop and comm...
Zymeworks Closes Theravance Acquisition and CVR Financing
PositiveOn September 22, 2026, Zymeworks entered into a Contingent Value Rights Agreement in connection with its merger, granting former stakeholders non-tradeable rights tied to future monetization and commercialization of ampreloxetine over a 10-year perio...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 16, 2026
